HRP20220231T1 - Spojevi i postupci za liječenje bakterijskih infekcija - Google Patents
Spojevi i postupci za liječenje bakterijskih infekcija Download PDFInfo
- Publication number
- HRP20220231T1 HRP20220231T1 HRP20220231TT HRP20220231T HRP20220231T1 HR P20220231 T1 HRP20220231 T1 HR P20220231T1 HR P20220231T T HRP20220231T T HR P20220231TT HR P20220231 T HRP20220231 T HR P20220231T HR P20220231 T1 HRP20220231 T1 HR P20220231T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- image
- optionally substituted
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 23
- 208000035143 Bacterial infection Diseases 0.000 title claims 2
- 208000022362 bacterial infectious disease Diseases 0.000 title claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 51
- 229910052739 hydrogen Inorganic materials 0.000 claims 19
- 239000001257 hydrogen Substances 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 16
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 11
- 125000000623 heterocyclic group Chemical group 0.000 claims 10
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 5
- 229910003827 NRaRb Inorganic materials 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- -1 C(O)NRdRe Chemical group 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000006413 ring segment Chemical group 0.000 claims 2
- MZAGXDHQGXUDDX-JSRXJHBZSA-N (e,2z)-4-ethyl-2-hydroxyimino-5-nitrohex-3-enamide Chemical group [O-][N+](=O)C(C)C(/CC)=C/C(=N/O)/C(N)=O MZAGXDHQGXUDDX-JSRXJHBZSA-N 0.000 claims 1
- XCUAIINAJCDIPM-XVFCMESISA-N N(4)-hydroxycytidine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=NO)C=C1 XCUAIINAJCDIPM-XVFCMESISA-N 0.000 claims 1
- 229910006074 SO2NH2 Inorganic materials 0.000 claims 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762502867P | 2017-05-08 | 2017-05-08 | |
| EP18726702.6A EP3630111B1 (en) | 2017-05-08 | 2018-05-08 | Compounds and methods for treating bacterial infections |
| PCT/US2018/031593 WO2018208769A1 (en) | 2017-05-08 | 2018-05-08 | Compounds and methods for treating bacterial infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220231T1 true HRP20220231T1 (hr) | 2022-04-29 |
Family
ID=62223332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220231TT HRP20220231T1 (hr) | 2017-05-08 | 2018-05-08 | Spojevi i postupci za liječenje bakterijskih infekcija |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US11046694B2 (https=) |
| EP (1) | EP3630111B1 (https=) |
| JP (1) | JP7058322B2 (https=) |
| KR (1) | KR102611447B1 (https=) |
| CN (1) | CN110709081B (https=) |
| AU (1) | AU2018266640B2 (https=) |
| CY (1) | CY1125340T1 (https=) |
| DK (1) | DK3630111T3 (https=) |
| EA (1) | EA038393B1 (https=) |
| ES (1) | ES2907858T3 (https=) |
| HR (1) | HRP20220231T1 (https=) |
| HU (1) | HUE057592T2 (https=) |
| IL (1) | IL270380B (https=) |
| LT (1) | LT3630111T (https=) |
| MA (1) | MA48743A (https=) |
| MX (1) | MX385203B (https=) |
| MY (1) | MY201377A (https=) |
| NZ (1) | NZ758200A (https=) |
| PE (1) | PE20200333A1 (https=) |
| PH (1) | PH12019502509A1 (https=) |
| PL (1) | PL3630111T3 (https=) |
| PT (1) | PT3630111T (https=) |
| SG (1) | SG11201909443YA (https=) |
| SI (1) | SI3630111T1 (https=) |
| SM (1) | SMT202200110T1 (https=) |
| TW (1) | TWI791018B (https=) |
| WO (1) | WO2018208769A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11905286B2 (en) | 2018-08-09 | 2024-02-20 | Antabio Sas | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
| SG11202101255UA (en) | 2018-08-09 | 2021-03-30 | Antabio Sas | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
| CN111675641B (zh) * | 2020-06-04 | 2023-09-08 | 宁夏农林科学院农业资源与环境研究所（宁夏土壤与植物营养重点实验室） | 单环β-内酰胺类化合物、单环内酰胺类化合物盐及其制备方法 |
| US12410166B2 (en) | 2021-05-07 | 2025-09-09 | Ningxia Academy Of Agriculture And Forestry Sciences | Sulfonylamidine substituted compounds and their use as beta-lactamase inhibitors |
| US11814385B2 (en) | 2021-06-25 | 2023-11-14 | University Of South Florida | Small molecule inhibitors targeting Clostridioides difficile sporulation |
| WO2025064681A1 (en) * | 2023-09-19 | 2025-03-27 | Entasis Therapeutics Inc. | Compounds and methods for treating bacterial infections |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUT74682A (en) | 1993-12-29 | 1997-01-28 | Pfizer | Diazabicyclic neurokinin antagonists and pharmaceutical compositions containing them |
| FR2812635B1 (fr) | 2000-08-01 | 2002-10-11 | Aventis Pharma Sa | Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens |
| FR2825705B1 (fr) | 2001-06-08 | 2005-05-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens |
| FR2835186B1 (fr) | 2002-01-28 | 2006-10-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases |
| US7439253B2 (en) * | 2002-12-06 | 2008-10-21 | Novexel | Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors |
| FR2848210B1 (fr) * | 2002-12-06 | 2007-10-19 | Aventis Pharma Sa | Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases |
| US7507727B2 (en) * | 2003-04-07 | 2009-03-24 | Cylene Pharmaceuticals, Inc. | Substituted quinobenzoxazine analogs and methods of using thereof |
| FR2914923B1 (fr) | 2007-04-12 | 2013-06-14 | Novexel | Nouveaux composes heterocycliques azotes,leur preparation et leur utilisation comme medicaments antibacteriens. |
| ES2533826T3 (es) | 2008-01-18 | 2015-04-15 | Merck Sharp & Dohme Corp. | Inhibidores de beta-lactamasa |
| FR2930553B1 (fr) | 2008-04-29 | 2010-05-21 | Novexel | Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases |
| EP2921559A1 (en) | 2008-06-19 | 2015-09-23 | Astra Zeneca Holding France | Use of (1r,2s,5r) 1,6-diazabicyclo [3.2.1]octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases |
| FR2936798B1 (fr) | 2008-10-03 | 2012-09-28 | Novexel | Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens. |
| FR2936951B1 (fr) | 2008-10-10 | 2010-12-03 | Novexel | Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments |
| FR2937034B1 (fr) * | 2008-10-10 | 2012-11-23 | Novexel | Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens |
| FR2951171A1 (fr) | 2009-10-09 | 2011-04-15 | Novexel | Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation |
| US9744160B2 (en) | 2011-07-26 | 2017-08-29 | Wockhardt Limited | Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor |
| EP2768503A1 (en) | 2011-07-26 | 2014-08-27 | Wockhardt Limited | Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor |
| RU2578370C2 (ru) | 2011-08-27 | 2016-03-27 | Вокхардт Лимитед | Производные 1,6- диазабицикло [3,2,1] октан-7-она и их применение при лечении бактериальных инфекционных болезней |
| MX340533B (es) * | 2011-08-30 | 2016-07-13 | Wockhardt Ltd | Derivados de 1,6- diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas. |
| EP3052497B1 (en) | 2011-09-13 | 2017-06-28 | Wockhardt Limited | Nitrogen containing compounds and their use |
| US8796257B2 (en) | 2011-12-02 | 2014-08-05 | Naeja Pharmaceutical Inc. | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors |
| EP2814483A2 (en) | 2012-02-15 | 2014-12-24 | Rempex Pharmaceuticals, Inc. | Methods of treating bacterial infections |
| US8916709B2 (en) | 2012-03-30 | 2014-12-23 | Cubist Pharmaceuticals, Inc. | 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors |
| US8969570B2 (en) | 2012-03-30 | 2015-03-03 | Cubist Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| TW201343645A (zh) | 2012-03-30 | 2013-11-01 | Cubist Pharm Inc | １，３，４－□二唑及１，３，４－噻二唑β－內醯胺酶抑制劑 |
| KR20150003777A (ko) | 2012-03-30 | 2015-01-09 | 큐비스트 파마슈티컬즈 인코포레이티드 | 이속사졸 β-락타마제 억제제 |
| AR090539A1 (es) * | 2012-04-02 | 2014-11-19 | Astrazeneca Ab | COMPUESTOS INHIBIDORES DE b LACTAMASA |
| RU2693898C2 (ru) | 2012-05-30 | 2019-07-05 | Мейдзи Сейка Фарма Ко., Лтд. | НОВЫЙ ИНГИБИТОР бета-ЛАКТАМАЗЫ И СПОСОБ ЕГО ПОЛУЧЕНИЯ |
| BR112015003592B1 (pt) | 2012-08-25 | 2020-04-14 | Wockhardt Ltd | derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infecções bacterianas |
| WO2014033561A1 (en) | 2012-09-03 | 2014-03-06 | Wockhardt Limited | Antibacterial compositions |
| WO2014122468A1 (en) | 2013-02-06 | 2014-08-14 | Astrazeneca Ab | Combination therapy for the treatment of nosocomial pneumonia |
| WO2014141132A1 (en) * | 2013-03-14 | 2014-09-18 | Naeja Pharmaceutical Inc. | NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS |
| KR102542392B1 (ko) | 2014-11-17 | 2023-06-09 | 엔타시스 테라퓨틱스 리미티드 | 내성 박테리아 감염의 치료를 위한 배합물 치료제 |
| CN114591223B (zh) | 2016-09-16 | 2025-01-24 | 恩塔西斯治疗有限公司 | β-内酰胺酶抑制剂化合物 |
-
2018
- 2018-05-08 NZ NZ758200A patent/NZ758200A/en unknown
- 2018-05-08 EP EP18726702.6A patent/EP3630111B1/en active Active
- 2018-05-08 DK DK18726702.6T patent/DK3630111T3/da active
- 2018-05-08 MY MYPI2019006163A patent/MY201377A/en unknown
- 2018-05-08 PL PL18726702T patent/PL3630111T3/pl unknown
- 2018-05-08 AU AU2018266640A patent/AU2018266640B2/en active Active
- 2018-05-08 LT LTEPPCT/US2018/031593T patent/LT3630111T/lt unknown
- 2018-05-08 MX MX2019013291A patent/MX385203B/es unknown
- 2018-05-08 US US16/611,065 patent/US11046694B2/en active Active
- 2018-05-08 SG SG11201909443Y patent/SG11201909443YA/en unknown
- 2018-05-08 HU HUE18726702A patent/HUE057592T2/hu unknown
- 2018-05-08 ES ES18726702T patent/ES2907858T3/es active Active
- 2018-05-08 CN CN201880030289.8A patent/CN110709081B/zh active Active
- 2018-05-08 MA MA048743A patent/MA48743A/fr unknown
- 2018-05-08 SI SI201830571T patent/SI3630111T1/sl unknown
- 2018-05-08 KR KR1020197035865A patent/KR102611447B1/ko active Active
- 2018-05-08 JP JP2020512769A patent/JP7058322B2/ja active Active
- 2018-05-08 HR HRP20220231TT patent/HRP20220231T1/hr unknown
- 2018-05-08 TW TW107115559A patent/TWI791018B/zh active
- 2018-05-08 EA EA201992370A patent/EA038393B1/ru unknown
- 2018-05-08 SM SM20220110T patent/SMT202200110T1/it unknown
- 2018-05-08 IL IL270380A patent/IL270380B/en unknown
- 2018-05-08 PT PT187267026T patent/PT3630111T/pt unknown
- 2018-05-08 PE PE2019002309A patent/PE20200333A1/es unknown
- 2018-05-08 WO PCT/US2018/031593 patent/WO2018208769A1/en not_active Ceased
-
2019
- 2019-11-08 PH PH12019502509A patent/PH12019502509A1/en unknown
-
2022
- 2022-02-23 CY CY20221100157T patent/CY1125340T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220231T1 (hr) | Spojevi i postupci za liječenje bakterijskih infekcija | |
| GEP20247646B (en) | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | |
| HRP20251156T1 (hr) | Supstituirani makrociklični spojevi i srodni postupci liječenja | |
| HRP20241197T1 (hr) | Makrociklični spojevi i primjene istih | |
| PH12021550167A1 (en) | Heterobicyclic compounds for inhibiting the activity of shp2 | |
| HRP20170154T1 (hr) | Analozi antibakterijskog aminoglikozida | |
| HRP20160852T1 (hr) | Biciklični heterociklični spojevi kao inhibitori protein tirozin kinaze | |
| ME02875B (me) | Inhibitori hcv polimeraze | |
| HRP20241540T1 (hr) | Pirolotriazinski spojevi koji djeluju kao inhibitor mnk | |
| ME02373B (me) | Biciklična heterociklična jedinjenja kao inhibitori protein tirozin kinaze | |
| HRP20221112T1 (hr) | Derivati benzodiazepina kao inhibitori rsv | |
| ATE526341T1 (de) | Makrozyklische verbindungen als antivirale mittel | |
| HRP20210895T1 (hr) | Inhibitori hpk1 i metode za njihovo korištenje | |
| ME02835B (me) | Antivirusna rsv jedinjenja | |
| AR073760A1 (es) | Derivados heterociclicos y metodos de uso de los mismos | |
| BR112014000563A2 (pt) | composto, composição farmacêutica, e, uso do composto | |
| MX2019004578A (es) | Oxisteroles y metodos de uso de los mismos. | |
| HRP20180483T1 (hr) | Spoj kinolona | |
| ME02453B (me) | Inhibitori protein kinaze | |
| WO2020113213A3 (en) | Cyclic pantetheine derivatives and uses thereof | |
| ME02800B (me) | Nova triciklična jedinjenja | |
| SE0202133D0 (sv) | Novel compounds | |
| PE20090648A1 (es) | Compuestos para el tratamiento de la hepatitis c | |
| GEP20207128B (en) | Aminothiazole derivatives useful as antiviral agents | |
| MX2010004293A (es) | Derivados de 6-aril/heteroalquiloxi benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nuevo uso principalmente como inhibidores de cmet. |